

Terumo invests ¥15 B to expand CDMO services outside Japan

01 November 2022 | News

The demand for high quality and reliable CDMO services for injectable drugs is expected to increase globally

Terumo Pharmaceutical Solutions (TPS), a leading manufacturer of injection, primary container, and infusion therapy devices, has announced that it will expand its contract development and manufacturing (CDMO) services for parenteral drugs to global customers.

Terumo is a well-established integrated CDMO in Japan offering end-to-end services for more than 20 years, supporting customers with pre-filled syringe (PFS) design, molding, drug preparation, filling, assembly, and final packaging for challenging biotech drugs and small molecules.

The company, which has three CDMO sites in Japan, stated that the expansion would involve engaging on projects that cover the early development stage to large scale commercial production for global pharmaceutical customers including assembly of PFS with devices like autoinjectors, needle safety devices, and supporting customers for regulatory submissions globally.

Terumo is investing to expand the CDMO production facilities for pre-filled syringes at its wholly owned subsidiary Terumo Yamaguchi Corporation. (Yamaguchi City). The total investment, including peripheral equipment, will be 15 billion yen. As a result, Terumo Yamaguchi D&D's production capacity will increase by 3.5 times compared to when the plant started operation in 2016.

The demand for high quality and reliable CDMO services for injectable drugs is expected to increase globally. Terumo with their unique integrated model and track record can offer customers a simple supply chain, reduce risk and time to market.